MICROCURES

MicroCures is rapidly advancing its three parallel programs for clinical trials. Multiple preclinical studies have demonstrated that the company's technology produces statistically significant improvement and acceleration of tissue repair in three therapeutic pathways with large unmet need markets: corneal, peripheral nerve, and dermal... This novel scientific approach offers the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications. Microcures has created a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike other regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures' technology directs and enhances the body's inherent tissue repair processes through local, non-systemic, and temporary modulation of cell motility... MicroCures has developed a proprietary siRNA-based drug candidate designed..

Also known as: MicroCures, Inc.